IMAGING OF PRIMARY OR RECURRENT GYNECOLOGICAL CANCER WITH [18F]FLUORTHANATRACE ([18F]FTT) PET/CT
Enrolling By Invitation
99 years or below
All
Phase
1
20 participants needed
1 Location
Brief description of study
Women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 30 evaluable subjects who have been recommended to start systemic therapy as part of their cancer treatment will participate in this study. Participants will undergo up to three [18F]FTT PET/CT scans. A baseline scan will be done prior to starting therapy. A second [18F]FTT PET/CT scan may be done 1-21 days after initiation of therapy to collect pilot data on the changes in FTT uptake with therapy. A third FTT scan may be performed when the patient progresses on therapy (e.g. PARP inhibitor). For each [18F]FTT PET/CT imaging session, participants will undergo a static skull base to mid-thigh scan starting approximately 60 minutes post injection of [18F]FTT.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: GYNECOLOGICAL CANCER
-
Age: 99 years or below
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833685
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245